ABOUT SCORPION

At Scorpion Therapeutics, we are working to expand the reach of precision medicine to more people with cancer, including cancers that are untreatable or treatment-resistant today. We are moving with equal parts urgency and rigor to change the status quo, drawing on our team’s expertise and drive to accelerate our impact on patients.

Our team is comprised of renowned experts in cancer biology, targeted oncology, and drug development – pioneers in cataloging and understanding the genomic events and cellular mechanisms that give rise to cancer; identifying and characterizing the molecular subtypes of disease; designing pharmacological interventions to stop these disease processes and speeding the clinical translation of new insights into transformative targeted therapies for patients.

We are working together to speed the next generation of targeted therapies to patients.

< Back to Intro

P. Joseph Campisi, Jr., J.D.

EVP, General Counsel and Secretary

Joseph Campisi, Jr., Esq. has more than 30 years of experience in mergers and acquisitions, collaborations, and securities offerings. Prior to joining Scorpion Therapeutics, Joseph was Senior Vice President and Deputy General Counsel at Bristol-Myers Squibb Company, where he oversaw the Transactional Practice Group of the BMS Law Department.

Read more

Adam Friedman, M.D., Ph.D.

President, Corporate Strategy & Business Development

Dr. Adam Friedman is an accomplished physician, scientist and life sciences entrepreneur with extensive experience in oncology. He currently serves as President, Corporate Strategy & Business Development, which follows his former role as interim CEO of Scorpion. Prior to joining the company, Dr. Friedman served as Director at Serien Therapeutics, a next-generation immuno-metabolism company.

Read more

Angel Guzman-Perez, Ph.D.

Head of Drug Discovery

Dr. Angel Guzman-Perez is the head of drug discovery at Scorpion Therapeutics, bringing extensive medicinal chemistry, drug discovery, and leadership experience. Prior to joining Scorpion, Dr. Guzman-Perez held leadership roles in Amgen’s research organization, serving as Executive Director, Head of Medicinal Chemistry and was responsible for the small-molecule portfolio across therapeutic areas.

Read more

Axel Hoos, M.D., Ph.D.

Chief Executive Officer

Dr. Axel Hoos is a distinguished physician-scientist, executive, entrepreneur and leader who became the CEO of Scorpion Therapeutics in August 2021. Prior to Scorpion, he served as Senior Vice President, R&D Governance Chair, and Therapeutic Area Head for oncology at GlaxoSmithKline Pharmaceuticals (GSK).

Read more

Erica L. Jackson, Ph.D.

EVP, Target Biology

Dr. Erica L. Jackson has spent the past 20 years leading teams and mentoring scientists in oncology target validation and large and small molecule drug discovery. Prior to joining Scorpion, Erica was Senior Director of Oncology Discovery at AbbVie, where she led a cross-site team of biologists responsible for all biology aspects of drug discovery from target ID through candidate nomination.

Read more

Guy E Padbury, Ph.D.

Chief Development Officer

Dr. Guy E. Padbury is the Chief Development Officer at Scorpion Therapeutics, a role to which he brings over 30 years of experience as a scientist and organizational leader in the pharmaceutical and biotechnology industries. Prior to Scorpion, Guy was Senior Vice President of Preclinical Development within Merck Research Laboratories.

Read more

Darrin Stuart, Ph.D.

Chief Scientific Officer

Dr. Darrin Stuart has spent the last 20 years leading and mentoring teams in small molecule drug discovery in the oncology therapeutic area. Darrin is the Chief Scientific Officer at Scorpion Therapeutics. Prior to joining Scorpion, Darrin was Executive Director of Cancer Biology and Drug Discovery at Novartis where he oversaw the oncology small molecule portfolio at the Cambridge, Massachusetts site.

Read more

Amanda Valentino

Chief People Officer

Amanda Valentino brings two decades of experience and leadership in talent acquisition, human resources and employee experience in the pharma/biotech industry. Prior to joining Scorpion, Amanda served as the Chief People Officer of Ambys Medicines, where she was responsible for designing the company’s approach to hiring and retaining talent.

Read more

Liron Bar-Peled, Ph.D.

Assistant Professor of Medicine, Harvard Medical School

Dr. Liron Bar-Peled is an Assistant Professor of Medicine at Harvard Medical School and the Cancer Center at Massachusetts General Hospital. His research focuses on deciphering fundamental mechanisms of stress signaling in cancer states and employing chemical proteomic platforms to discover new therapies for cancer.

Read more

Keith Flaherty, M.D.

Professor of Medicine, Harvard Medical School

Dr. Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. As described in the more than 300 peer-reviewed primary research reports he has authored or co-authored, Dr. Flaherty and colleagues made several seminal observations…

Read more

Gaddy Getz, Ph.D.

Professor of Medicine, Harvard Medical School Member, Broad Institute of MIT and Harvard

Dr. Gaddy Getz is an internationally acclaimed leader in cancer genomics and is pioneering widely used tools for analyzing cancer genomes. Dr. Getz is an institute member of the Broad Institute of MIT and Harvard, where he directs the Cancer Genome Computational Analysis Group. Dr. Getz is a Professor of Pathology at Harvard Medical School, and he is a faculty member and Director of Bioinformatics at the Massachusetts General Hospital (MGH) Cancer Center and Department of Pathology.

Read more

Gary Glick, Ph.D.

Co-Founder

Dr. Gary Glick co-founded Scorpion Therapeutics. Gary started his career as a faculty member at the University of Michigan in Ann Arbor, where he is currently the Werner E. Bachmann emeritus professor of chemistry. While at Michigan, Gary founded Lycera Corp. to develop new therapies for inflammation and cancer based on small molecules that modulate cellular metabolism.

Read more

Annie Mitsak, Ph.D.

Observer
Omega Funds

Shelley Chu, M.D., Ph.D.

Independent Director
LSVP, Head of Biotech

Keith Flaherty, M.D.

Director
Harvard Medical School

Jean-François Formela, M.D.

Director
Atlas Venture

Axel Hoos, M.D., Ph.D.

Director
CEO, Scorpion Therapeutics

Arjun Goyal, M.D., M.PHIL, M.B.A.

Director
Vida Ventures

Oleg Nodelman

Director
EcoR1

Otello Stampacchia

Director
Omega Funds

Aaron Davis

Observer
Boxer Capital

Meredith Fisher, Ph.D.

Observer
Mass General Brigham Ventures

Tim Haines

Observer
Abingworth

Chelsea Place Johnson, Ph.D.

Observer
Atlas Venture

William Sellers, M.D.

Observer
Broad Institute
< Back to Intro

Investors